Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial
Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial PR Newswire MONT-SAINT-GUIBERT, Belgium, January 9, 2014 MONT-SAINT-GUIBERT, Belgium , January 9, 2014 /PRNewswire/ — Cardio3 BioSciences (C3BS) ( NYSE Euronext Brussels and Paris : CARD ), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary regenerative medicine product C3BS-CQR-1 (C-Cure) as a treatment targeting heart failure. CHART-2, the Company’s second Phase III clinical trial, is intended to assess in the US, the efficacy of C3BS-CQR-1 as a treatment for heart failure of ischemic origin […]